Cervomed Inc. quarterly report, Q1 FY2021

Business context and reporting period

This is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2021—not a filing identified as Cervomed Inc. Diffusion is a clinical-stage biopharmaceutical company developing TSC, intended to improve oxygen delivery to tissues, and early-stage candidate DFN-529. It reported no product revenue.

Financial results and liquidity

At March 31, 2021, working capital was $45.2 million, total liabilities were $2.57 million, and accumulated deficit was $110.6 million. The filing reports no credit facilities or committed borrowing capital. Cash rose by $28.12 million during the quarter, chiefly from $31.1 million net proceeds from a February stock offering and $2.2 million from warrant exercises. Shares outstanding increased to 101.9 million from 64.0 million at year-end 2020. Management expected cash on hand to fund operations and planned trials through 2023, while also stating additional financing will likely be needed to complete TSC development.

No profit or operating margin is meaningful because the company had no product sales. Debt balances are not reported; the filing states there were no credit facilities in place.

Material changes versus the prior comparable period

• R&D expense increased $1.38 million. Management attributed the rise mainly to $0.7 million for the TSC COVID Trial, $0.6 million for the TSC TCOM Trial, higher manufacturing costs, and increased salaries; wind-downs of the stroke and GBM trials partly offset the increase.
• G&A expense increased $0.35 million, reflecting higher personnel, stock compensation, professional fees, and costs associated with former executive separations that management said would not recur.
• Net loss widened by $2.09 million. The comparison also reflects a $0.36 million income tax benefit in Q1 2020 that was not repeated in 2021 because the available benefit had been fully realized in prior periods.
• Operating cash use increased by $1.67 million. Financing cash inflows rose substantially following the February 2021 equity offering and warrant exercises.

Outlook, commentary, risks and unusual items

• In March, the company completed dosing of 30 participants in the TSC TCOM Phase 1 trial and expected topline results by the end of Q2 2021. It completed the 24-patient TSC COVID Trial in February; the primary safety endpoint was met, with no dose-limiting toxicities or serious adverse events reported. Secondary endpoint analyses were ongoing.
• Two further TSC oxygenation trials were planned for the second half of 2021. If one or more trials produced positive data, management expected to identify up to two hypoxia-related indications in Q4 2021 and begin studies in Q1 2022. These were expectations, not assured outcomes.
• The company has incurred losses since inception and expects substantial future losses and increased development spending. If financing is unavailable, it may need to delay, reduce, or end programs, seek collaborations on potentially less favorable terms, pursue strategic alternatives, or cease operations.
• On May 6, 2021, after quarter-end, Nasdaq notified the company that its share price had closed below $1 for 30 consecutive business days. The company had until November 2, 2021 to regain compliance; it was considering alternatives, including a possible reverse stock split. Delisting could impair trading liquidity and future fundraising.
• A former executive’s arbitration, scheduled for August 16, 2021, seeks damages in an undetermined amount. The company disputes the claims but said it could not predict the outcome or potential loss; an adverse resolution could materially affect its financial position.
• Management said disclosure controls were effective at quarter-end and reported no material change in internal control over financial reporting. The COVID-19 pandemic had no material impact on Q1 estimates, but future effects remained uncertain.

Important facts for investors to verify

• Confirm the issuer identity: the supplied filing is for Diffusion Pharmaceuticals Inc., while the request metadata names Cervomed Inc.
• Track TSC trial readouts, timing, safety findings, and whether results support the planned indication studies.
• Assess whether the cash runway through 2023 remains adequate as clinical spending rises and whether further financing is required.
• Monitor Nasdaq bid-price compliance and any reverse split or other listing action.
• Review developments and any estimated exposure in the pending arbitration.
• Consider dilution from the large 2021 share issuance and outstanding warrants and options.